Bio-Rad Laboratories, Inc. (NYSE:BIO) reported better-than-expected second-quarter financial results on Thursday.
Bio-Rad Laboratories reported quarterly earnings of $2.61 per share which beat the analyst consensus estimate of $1.76 per share. The company reported quarterly sales of $651.600 million which beat the analyst consensus estimate of $615.110 million.
Bio-Rad Laboratories narrowed its FY2025 sales guidance from $2.541 billion-$2.606 billion to $2.567 billion-$2.593 billion.
Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, said, “In a highly dynamic environment, we delivered solid quarterly results, both in terms of revenue and operating margin, through focused execution and careful expense management. …